- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Lenvatinib (thyroid cancer) – July 2018
Lenvatinib (thyroid cancer): Capsule 4 mg (as mesilate); Capsule 10 mg (as mesilate); Lenvima®
Last updated
26 October 2018